Lab test

MMA Fighter Blood Test: HIV, Hepatitis B&C

The MMA Fighter Blood Test is a three-part blood panel that screens for HIV, hepatitis B, and hepatitis C.

Typical price

From $158

Results

1-3 business days

Preparation

See preparation notes below

Sample

Blood draw or sample collection at a local center

The MMA Fighter Blood Test is a three-part blood panel that screens for HIV, hepatitis B, and hepatitis C. It is commonly ordered by fighters and other combat-sport athletes who must document negative infectious disease testing before competing or licensing. The hepatitis B component looks for surface antigen, and the hepatitis C component looks for antibodies, while the HIV component uses antigen and antibody detection. Collecting all three from one blood draw simplifies the process. Results are screening information that should be reviewed with a healthcare provider.

• HIV-1/2 antigen/antibody Screens for HIV infection using antigen and antibody detection.
• Hepatitis B surface antigen (HBsAg) Detects a marker that can indicate current hepatitis B infection.
• Hepatitis C antibody Screens for antibodies associated with hepatitis C infection.

• Combat-sport athletes meeting a pre-competition or licensing requirement
• People with a possible exposure to HIV or viral hepatitis
• Individuals whose healthcare provider recommends viral hepatitis screening
• People without symptoms who want confidential infectious disease testing
• Those with a partner or household contact diagnosed with HIV or hepatitis

• No fasting is required for this panel
• A standard blood draw is used to collect the sample
• Inform the lab of any medications you take
• Follow any specific requirements supplied with your test order

Each of the three components is reported separately. A negative result generally means the marker was not detected, while a positive HIV or hepatitis B surface antigen result may indicate infection. A positive hepatitis C antibody result may reflect current or past exposure and usually prompts additional testing. Detection windows vary, so timing matters. Because this is a screening panel, discuss all results with a healthcare provider before drawing conclusions.

• Alabama
• Alaska
• Arizona
• Arkansas
• California
• Colorado
• Connecticut
• Delaware
• Florida
• Georgia